Cargando…

Comparing the diagnostic performance of QuantiFERON-TB Gold Plus with QFT-GIT, T-SPOT.TB and TST: a systematic review and meta-analysis

BACKGROUND: QuantiFERON-TB Gold Plus (QFT-Plus) is an important test that has emerged in recent years for detecting TB infection. We conducted a review to compare the sensitivity, specificity and positive rate of QFT-Plus with that of QuantiFERON-TB Gold In-Tube (QFT-GIT), T-cell spot of tuberculosi...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yu, Zhou, Guozhong, Shi, Wei, Shi, Weili, Hu, Meijun, Kong, Defu, Long, Rong, He, Jian, Chen, Nan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862551/
https://www.ncbi.nlm.nih.gov/pubmed/36670347
http://dx.doi.org/10.1186/s12879-023-08008-2
_version_ 1784875118670905344
author Zhang, Yu
Zhou, Guozhong
Shi, Wei
Shi, Weili
Hu, Meijun
Kong, Defu
Long, Rong
He, Jian
Chen, Nan
author_facet Zhang, Yu
Zhou, Guozhong
Shi, Wei
Shi, Weili
Hu, Meijun
Kong, Defu
Long, Rong
He, Jian
Chen, Nan
author_sort Zhang, Yu
collection PubMed
description BACKGROUND: QuantiFERON-TB Gold Plus (QFT-Plus) is an important test that has emerged in recent years for detecting TB infection. We conducted a review to compare the sensitivity, specificity and positive rate of QFT-Plus with that of QuantiFERON-TB Gold In-Tube (QFT-GIT), T-cell spot of tuberculosis assay (T-SPOT.TB) and Tuberculin test (TST). METHODS: PubMed and Embase were searched, without language restrictions, from 1 January 2015 to 31 March 2022 using “Mycobacterium tuberculosis Infections” and “QuantiFERON-TB-Plus” as search phrases. We estimated the sensitivity from studies of patients with active tuberculosis, specificity from studies of populations with very low risk of TB exposure, and positive rate from studies of high-risk populations. The methodological quality of the eligible studies was assessed, and a random-effects model meta-analysis was used to determine the risk difference (RD). We assessed the pooled rate by using a random-effects model. This study was registered in PROSPERO (CRD 42021267432). RESULTS: Of 3996 studies, 83 were eligible for full-text screening and 41 were included in the meta-analysis. In patients with active TB, the sensitivity of QFT-Plus was compared to that of QFT-GIT and T-SPOT.TB, respectively, and no statistically differences were found. In populations with a very low risk of TB exposure, the specificity of QFT-Plus was compared with that of QFT-GTI and T-SPOT.TB, respectively, and no statistically differences were found. Two studies were eligible to compare the specificity of the QFT-Plus test with that of the TST test, and the pooled RD was 0.12 (95% CI 0.02 to 0.22). In high-risk populations, 18 studies were eligible to compare the positive rate of the QFT-Plus test with that of the QFT-GIT test, and the pooled RD was 0.02 (95% CI 0.01 to 0.03). The positive rate of QFT-Plus was compared with that of T-SPOT.TB and TST groups, and no statistically differences were found. CONCLUSIONS: The diagnostic performance of QFT-Plus was similar to that of QFT-GIT and T-SPOT.TB, but was slightly more specific than TST. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-023-08008-2.
format Online
Article
Text
id pubmed-9862551
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-98625512023-01-22 Comparing the diagnostic performance of QuantiFERON-TB Gold Plus with QFT-GIT, T-SPOT.TB and TST: a systematic review and meta-analysis Zhang, Yu Zhou, Guozhong Shi, Wei Shi, Weili Hu, Meijun Kong, Defu Long, Rong He, Jian Chen, Nan BMC Infect Dis Research BACKGROUND: QuantiFERON-TB Gold Plus (QFT-Plus) is an important test that has emerged in recent years for detecting TB infection. We conducted a review to compare the sensitivity, specificity and positive rate of QFT-Plus with that of QuantiFERON-TB Gold In-Tube (QFT-GIT), T-cell spot of tuberculosis assay (T-SPOT.TB) and Tuberculin test (TST). METHODS: PubMed and Embase were searched, without language restrictions, from 1 January 2015 to 31 March 2022 using “Mycobacterium tuberculosis Infections” and “QuantiFERON-TB-Plus” as search phrases. We estimated the sensitivity from studies of patients with active tuberculosis, specificity from studies of populations with very low risk of TB exposure, and positive rate from studies of high-risk populations. The methodological quality of the eligible studies was assessed, and a random-effects model meta-analysis was used to determine the risk difference (RD). We assessed the pooled rate by using a random-effects model. This study was registered in PROSPERO (CRD 42021267432). RESULTS: Of 3996 studies, 83 were eligible for full-text screening and 41 were included in the meta-analysis. In patients with active TB, the sensitivity of QFT-Plus was compared to that of QFT-GIT and T-SPOT.TB, respectively, and no statistically differences were found. In populations with a very low risk of TB exposure, the specificity of QFT-Plus was compared with that of QFT-GTI and T-SPOT.TB, respectively, and no statistically differences were found. Two studies were eligible to compare the specificity of the QFT-Plus test with that of the TST test, and the pooled RD was 0.12 (95% CI 0.02 to 0.22). In high-risk populations, 18 studies were eligible to compare the positive rate of the QFT-Plus test with that of the QFT-GIT test, and the pooled RD was 0.02 (95% CI 0.01 to 0.03). The positive rate of QFT-Plus was compared with that of T-SPOT.TB and TST groups, and no statistically differences were found. CONCLUSIONS: The diagnostic performance of QFT-Plus was similar to that of QFT-GIT and T-SPOT.TB, but was slightly more specific than TST. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12879-023-08008-2. BioMed Central 2023-01-20 /pmc/articles/PMC9862551/ /pubmed/36670347 http://dx.doi.org/10.1186/s12879-023-08008-2 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Zhang, Yu
Zhou, Guozhong
Shi, Wei
Shi, Weili
Hu, Meijun
Kong, Defu
Long, Rong
He, Jian
Chen, Nan
Comparing the diagnostic performance of QuantiFERON-TB Gold Plus with QFT-GIT, T-SPOT.TB and TST: a systematic review and meta-analysis
title Comparing the diagnostic performance of QuantiFERON-TB Gold Plus with QFT-GIT, T-SPOT.TB and TST: a systematic review and meta-analysis
title_full Comparing the diagnostic performance of QuantiFERON-TB Gold Plus with QFT-GIT, T-SPOT.TB and TST: a systematic review and meta-analysis
title_fullStr Comparing the diagnostic performance of QuantiFERON-TB Gold Plus with QFT-GIT, T-SPOT.TB and TST: a systematic review and meta-analysis
title_full_unstemmed Comparing the diagnostic performance of QuantiFERON-TB Gold Plus with QFT-GIT, T-SPOT.TB and TST: a systematic review and meta-analysis
title_short Comparing the diagnostic performance of QuantiFERON-TB Gold Plus with QFT-GIT, T-SPOT.TB and TST: a systematic review and meta-analysis
title_sort comparing the diagnostic performance of quantiferon-tb gold plus with qft-git, t-spot.tb and tst: a systematic review and meta-analysis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9862551/
https://www.ncbi.nlm.nih.gov/pubmed/36670347
http://dx.doi.org/10.1186/s12879-023-08008-2
work_keys_str_mv AT zhangyu comparingthediagnosticperformanceofquantiferontbgoldpluswithqftgittspottbandtstasystematicreviewandmetaanalysis
AT zhouguozhong comparingthediagnosticperformanceofquantiferontbgoldpluswithqftgittspottbandtstasystematicreviewandmetaanalysis
AT shiwei comparingthediagnosticperformanceofquantiferontbgoldpluswithqftgittspottbandtstasystematicreviewandmetaanalysis
AT shiweili comparingthediagnosticperformanceofquantiferontbgoldpluswithqftgittspottbandtstasystematicreviewandmetaanalysis
AT humeijun comparingthediagnosticperformanceofquantiferontbgoldpluswithqftgittspottbandtstasystematicreviewandmetaanalysis
AT kongdefu comparingthediagnosticperformanceofquantiferontbgoldpluswithqftgittspottbandtstasystematicreviewandmetaanalysis
AT longrong comparingthediagnosticperformanceofquantiferontbgoldpluswithqftgittspottbandtstasystematicreviewandmetaanalysis
AT hejian comparingthediagnosticperformanceofquantiferontbgoldpluswithqftgittspottbandtstasystematicreviewandmetaanalysis
AT chennan comparingthediagnosticperformanceofquantiferontbgoldpluswithqftgittspottbandtstasystematicreviewandmetaanalysis